脑机接口概念股午后持续走低，爱朋医疗（300753）跌近10%，均普智能跌超7%，荣泰健康 （603579）跌超6%，诚益通（300430）、三博脑科（301293）、翔宇医疗跟跌。 ...

Core Insights - The medical beauty sector experienced a slight increase of 0.53% on May 8, with a total capital outflow of 224.7 million [1] - A total of 43 stocks in the sector rose, while 21 stocks declined [1] Top Gainers - The top ten gainers in the sector included: - Aipeng Medical: +13.1% - Haochen Medical: +9.85% - Guangyunda: +9.8% - ST Jingfeng: +5.01% - ST Biological: +4.98% - Hangzhou Jiebai: +4.34% - Langzi Co.: +4.11% - Hanyu Pharmaceutical: +2.7% - Xinyaqiang: +1.57% - Dezhan Health: +1.29% [1] Top Losers - The stocks with the largest declines included: - Hanshang Group: -9.99% - Lafang Cosmetics: -6.79% - Changshan Pharmaceutical: -5.7% - ST Suwu: -4.84% - Chaohongji: -4.75% [1]

脑机接口概念股盘初冲高，爱朋医疗（300753）涨超15%，荣泰健康（603579）、麒盛科技（603610） 涨停，南京熊猫（600775）、诚益通（300430）跟涨。 暗盘资金正涌入这些股票，点击速看>>> ...

Market Overview - The Shanghai Composite Index is at 3305.11 points, below the six-month moving average, with a change of 0.80% [1] - The total trading volume of A-shares is 646.819 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 272 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Zhongcheng Technology: 14.42% deviation, with a price increase of 14.99% [1] - Oulutong: 10.01% deviation, with a price increase of 11.78% [1] - Jiusheng Electric: 9.22% deviation, with a price increase of 19.97% [1] Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Yongdong Co., Sumeida, and Yuhua Tian, which have just crossed the six-month line [1] Additional Stocks with Notable Performance - Other stocks with notable performance include: - Benlang New Materials: 8.45% deviation, with a price increase of 10.35% [1] - Quanzhu Co.: 8.00% deviation, with a price increase of 9.85% [1] - Chuanrun Co.: 7.95% deviation, with a price increase of 10.03% [1]

二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1400 | 0.0108 | -1396.3 | 0.0096 | | 每股净资产（元） | 5.4 | 5.53 | -2.35 | 5.45 | | 每股公积金(元) | 2.62 | 2.62 | 0 | 2.62 | | 每股未分配利润(元) | 1.37 | 1.57 | -12.74 | 1.50 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.65 | 0.88 | -26.14 | 0.94 | | 净利润(亿元) | -0.18 | 0.01 | -1900 | 0.01 | | 净资产收益率(%) | -2.55 | 0.19 | -1442.11 | 0.18 | 数据四舍五入，查看更多财务数据>> | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | ...

为充分尊重投资者，提升公司与投资者的交流效率和针对性，现就公司本次业绩 说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登 录深圳证券交易所互动易平台（http://irm.cninfo.com.cn）"云访谈"栏目，进入问题 征集专题页面进行提问。公司将在本次业绩说明会上，在信息披露允许的范围内对投 资者普遍关注的问题进行回答。 江苏爱朋医疗科技股份有限公司 关于举行2024年度暨2025年第一季度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）已于2025年4月19日在巨潮 资讯网（http://www.cninfo.com.cn）上披露了《2024年年度报告》全文及其摘要，于 2025年4月29日披露了《2025年第一季度报告》。 为了便于投资者更全面地了解公司2024年度及2025年第一季度经营情况，公司定 于2025年5月13日（星期二）16:00-17:00 举行2024年度暨2025年第一季度网上业绩说明 会，本次业绩说明会将通过深圳证券交易所提供的"互 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-020 江苏爱朋医疗科技股份有限公司 关于2025年第一季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）根据《深圳证券交易所创业 板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司 规范运作》《创业板上市公司业务办理指南第2号——定期报告披露相关事宜》《企业 会计准则》等相关法律法规以及公司相关会计政策的规定，基于谨慎性原则，为真实、 准确、客观地反映公司的财务、资产和经营状况，对截止2025年3月31日的合并报表范 围内相关资产计提资产减值准备。现将具体情况公告如下： 一、本次计提资产减值准备情况概述 （二）本次计提资产减值准备的资产范围和总金额 （一）本次计提资产减值准备的原因 根据《企业会计准则》及公司会计政策的相关规定，为公允反映公司各类资产的 价值，公司对合并范围内截止2025年3月31日的各类资产进行全面清查，对各类资产的 可变现性进行充分的评估和分析，认为上述资产中部分资产存在一定的 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-018 江苏爱朋医疗科技股份有限公司 第三届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、 监事会会议召开情况 江苏爱朋医疗科技股份有限公司（以下简称"公司"）第三届监事会第十一次会 议通知及会议材料于2025年4月17日以邮件形式向公司全体监事发出，会议于2025年4 月27日在上海市闵行区联航路1188号3号楼公司会议室以现场结合通讯的方式召开。 本次会议应出席监事3人，实际出席监事3人，会议由监事会主席袁新闯先生主持，会 议出席人数、召集、召开和表决程序符合《中华人民共和国公司法》等相关法律法规 以及《公司章程》的规定。 二、监事会会议审议情况 本次会议以记名方式投票表决，逐项审议通过以下议案： 1、审议通过《2025年第一季度报告》 监事会认为：董事会编制和审核公司2025年第一季度报告的程序符合法律、行政 法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况，没 有虚假记载、误导性陈述或者重大遗漏。具体内容详见公司同日于巨潮资讯网 （w ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2025-017 江苏爱朋医疗科技股份有限公司 第三届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏爱朋医疗科技股份有限公司（以下简称"公司"）第三届董事会第十一次 会议通知及会议材料于2025年4月17日以邮件形式向公司全体董事发出，会议于2025 年4月27日在上海市闵行区联航路1188号3号楼公司会议室以现场结合通讯的方式召 开。本次会议应出席董事7人，实际出席董事7人。会议由董事长王凝宇先生主持， 公司监事、高管列席了本次会议，会议出席人数、召集、召开和表决程序符合《中 华人民共和国公司法》等相关法律法规以及《江苏爱朋医疗科技股份有限公司章程》 的相关规定。 二、董事会会议审议情况 本次会议以记名方式投票表决，逐项审议以下议案： 1、审议通过《2025年第一季度报告》 董事会审议通过了《2025年第一季度报告》，认为公司2025年第一季度报告真 实反映了公司2025年第一季度的财务状况和经营成果，不存在虚假记载、误导性陈 述或重大遗漏。该议案 ...

Financial Performance - The company's revenue for Q1 2025 was ¥64,821,886.38, a decrease of 26.13% compared to ¥87,752,962.00 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥17,649,164.17, representing a decline of 1,400.65% from a profit of ¥1,356,953.49 in the previous year[4] - Total operating revenue decreased to ¥64,821,886.38 from ¥87,752,962.00, representing a decline of approximately 26.1% year-over-year[19] - Net profit for the period was a loss of ¥18,570,429.48, compared to a profit of ¥1,127,308.15 in the previous period, indicating a significant downturn[22] - The weighted average return on equity was -2.55%, a decrease of 2.74% from 0.19% in the same period last year[4] - The company reported a basic and diluted earnings per share of -0.1400, compared to 0.0108 in the previous period, indicating a significant decline in profitability[22] Cash Flow and Liquidity - The net cash flow from operating activities improved by 40.37%, amounting to -¥38,197,292.23 compared to -¥64,053,023.05 in Q1 2024[4] - Cash received from sales of goods and services increased to ¥72,290,849.98 from ¥69,016,477.25, showing a growth of approximately 3.3%[23] - The net increase in cash and cash equivalents for the period was -$121,980,152.39, compared to -$152,951,984.98 in the previous period[24] - The beginning balance of cash and cash equivalents was $201,635,257.87, slightly up from $200,896,344.58 in the prior period[24] - The ending balance of cash and cash equivalents stood at $79,655,105.48, significantly higher than $47,944,359.60 from the previous period[24] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥846,107,210.40, down 2.01% from ¥863,485,234.50 at the end of the previous year[4] - Current assets decreased to CNY 444,762,411.59 from CNY 458,436,768.88, indicating a decline of approximately 2.9%[16] - The total liabilities of the company as of March 31, 2025, were CNY 127,437,036.38, compared to CNY 125,619,973.03 at the beginning of the period[16] - Total liabilities increased slightly to ¥156,797,876.21 from ¥155,622,128.21, showing a marginal rise of about 0.8%[19] - The total equity attributable to shareholders decreased to ¥681,161,935.57 from ¥699,659,442.36, a decline of approximately 2.6%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,629[9] - The largest shareholder, Wang Ningyu, holds 28.62% of the shares, amounting to 36,069,811 shares, with 27,052,358 shares pledged[9] - The company reported a total of 43,614,451 shares under lock-up agreements, with 5,404,853 shares released during the period[13] - The number of shares held by the top 10 shareholders was significant, with the largest shareholder holding 9,017,453 shares[12] Operating Expenses - Sales expenses increased by 41.56% to ¥35,058,141.07, primarily due to increased market investment and maintenance costs[7] - Total operating costs slightly increased to ¥86,653,651.22 from ¥86,636,436.82, with operating costs specifically decreasing to ¥24,692,282.96 from ¥29,912,167.64, a reduction of about 17.5%[19] - Research and development expenses rose to ¥8,829,562.22 from ¥7,677,023.64, reflecting an increase of about 15.0% year-over-year[19] Investment and Income - The company reported a significant increase in investment income, which rose by 703.14% to ¥683,600.98 compared to ¥85,115.95 in Q1 2024[7] - The company recorded a total of ¥300,618.72 in non-recurring gains and losses for the reporting period[5] Other Information - The first quarter report was not audited, indicating a potential area of concern for investors[24] - The company will implement new accounting standards starting in 2025, which may affect financial reporting[24] - The company's short-term borrowings increased to CNY 58,344,832.64 from CNY 48,444,832.64, reflecting a rise of approximately 20%[16] - Accounts receivable slightly increased to CNY 159,878,195.76 from CNY 156,838,960.88, showing a growth of about 1.3%[15] - The company's long-term equity investments decreased slightly from CNY 52,393,867.86 to CNY 51,669,435.37, a decline of about 1.4%[16] - The company has not disclosed any new product developments or market expansion strategies in the current report[14]